Argenx Share Price closed 31% higher upon Positive Trial Data for CIDP

Today Argenx, an Aescap Life Sciences company, has announced positive results for its final clinical trial in patients diagnosed with CIDP (chronic inflammatory demyelinating polyneuropathy).